Endocrine Abstracts

It is common practice to attempt withdrawal of dopamine agonist (DA) therapy in patients with microprolactinomas who have achieved sustained normoprolactinaemia. There is, however little evidence to indicate which patients might attain long-term remission. The aim of this prospective study was to identify clinical factors that might predict such remission.We recruited 40 patients (39 females and 1 male, age 24-60 years) with a diagnosis of microprolactin...

Background: Withdrawal of dopamine agonist (DA) therapy in the management of microprolactinoma is common practice. It is unclear however which patients are likely to attain long term remission.Aims: The aim of this prospective study was to identify clinical factors that might predict long term remission.Subjects: Fourty subjects (39 female, aged 24–60 years) with microprolactinoma; all had been normoprolactinaemic on DA therap...